<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302532</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT04302532</nct_id>
  </id_info>
  <brief_title>Coenzyme q 10 and Fertility Outcome in Women With Clomiphene Resistant PCOS</brief_title>
  <official_title>Combined Coenzyme Q10 and Clomiphene Citrate for Ovulation Induction in Clomiphene-citrate-resistant Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karachi Medical and Dental College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karachi Medical and Dental College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effect of coenzyme q 10 on ovulation and subsequent pregnancy in&#xD;
      women with polycystic ovarian syndrome. Half of the participants will receive coq10 and&#xD;
      ovulation induction with clomiphene and other half would receive a placebo with clomiphene.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of ovulating women</measure>
    <time_frame>1-2 months</time_frame>
    <description>transvaginal ultrasound as the disappearance of the leading follicle, presence of follicular fluid in the Douglas pouch and midluteal progesterone &gt;5 pg/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of pregnancies</measure>
    <time_frame>1-2 months</time_frame>
    <description>ultrasound visualization of gestational sac with pulsating fetal pole</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Coenzyme q10</condition>
  <arm_group>
    <arm_group_label>Clomiphene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clomiphene citrate 150 mg once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clomiphene and coenzyme q10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clomiphene citrate 150 mg once a day for 5 days and coenzyme q 10 120 mg each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>antioxidant used to decrease oxidative stress and improve fertility prospects</description>
    <arm_group_label>clomiphene and coenzyme q10</arm_group_label>
    <other_name>celeron sr</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene citrate</intervention_name>
    <description>ovulation induction drug</description>
    <arm_group_label>Clomiphene</arm_group_label>
    <arm_group_label>clomiphene and coenzyme q10</arm_group_label>
    <other_name>clomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of polycystic ovarian syndrome PCOS based on the revised 2003 consensus on&#xD;
             diagnostic criteria and long-term health risks related to PCOS (2003).&#xD;
&#xD;
          -  All women were previously treated with 100 mg of CC daily for 5 days per cycle, for&#xD;
             two to three cycles with persistent anovulation or ovulate with very thin endometrium&#xD;
             &lt;5 mm at the time of hCG administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-consenting.&#xD;
&#xD;
          -  known autoimmune disorders&#xD;
&#xD;
          -  prior treatment of endometriosis or surgery to reproductive tract&#xD;
&#xD;
          -  prior history of pelvic inflammatory disease&#xD;
&#xD;
          -  those with tubal factors and uterine factors as assessed on history and confirmed by&#xD;
             normal hysterosalpingogram.&#xD;
&#xD;
          -  Thyroid disorder as assessed by history examination and TSH level&#xD;
&#xD;
          -  Patients with raised FSH&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rubina Izhar</last_name>
    <role>Study Director</role>
    <affiliation>Aziz Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aziz medical center</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karachi Medical and Dental College</investigator_affiliation>
    <investigator_full_name>samia husain</investigator_full_name>
    <investigator_title>clinical investigator</investigator_title>
  </responsible_party>
  <keyword>ovulation induction</keyword>
  <keyword>coenzyme q10</keyword>
  <keyword>pregnancy rate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

